Sudip Chaudhuri from the Indian Institute of Management, Calcutta published a paper on December 16, 2023, discussing challenges in #covid19 vaccine supply for import-dependent developing countries, particularly in Africa. Emphasizing the need for local production, the paper reviews ongoing efforts and calls for proactive measures, including government intervention, to build manufacturing capacities. Read more
Assessing Antibiotic Availability in Pakistan: Public vs Private Healthcare Disparities
A study led by Sunaina Rafi explores the availability of essential antibiotics in public and private healthcare sectors in Pakistan. Conducted between August 15 and September 10, 2020, the research categorizes 103 antibiotics into Access, Watch, Reserve, and anti-tuberculosis groups. Findings reveal significant challenges, with public facilities showing a mean on-spot availability of 23.76%, contrasting ...
WHO Exposes Health Threats: Substandard Meds | Science in 5 Ep.110
World Health Organization (WHO)’s Science in 5 | Ep.110 Dive into the crucial topic of substandard medical products and falsified treatments. Learn how WHO safeguards your health. Pernette Bourdillon Esteve breaks it down in this eye-opening episode!
Raffaella’s Literature Update
The following message is courtesy of Dr Raffaella Ravinetto, Public Health Department, Institute of Tropical Medicine Antwerp, Belgium. Ref. Cavany S, Nanyonga S, Hauk C, Lim C, Tarning J, Sartorius B, Dolecek C, Caillet C, Newton PN, Cooper BS. The uncertain role of substandard and falsified medicines in the emergence and spread of antimicrobial resistance. Nat ...
5th International PPRI Conference: Vienna 2024!
Join the 5th International PPRI Conference in Vienna on April 25-26, 2024! Engage with top-tier academics, policymakers, and stakeholders to explore innovative pharmaceutical policies for affordable access to medicines. Submit abstracts by January 15, 2024, for a chance to present in dedicated sessions. Details at https://ppri.goeg.at/ppriconference2024. Don’t miss the chance to shape future policies!
Happy Holidays, Quamed Community! See You in 2024
To our incredible Quamed community: as we embrace the magic of Christmas, we’re taking some time off to cherish moments with loved ones. Our offices will be closed from December 22nd, and we’ll return on January 2nd, rejuvenated and eager to continue our journey with you. Thank you for being with us! May your holidays ...
Introducing QUAMED’s Milestone: Issuance of the First 2 QCP Certificates
QUAMED is proud to announce that we have issued the first 2 QCP certificates. Our Independent Decision Committee (IDC) has issued a QCP GSDP certificate to BaDM, a pharmaceutical distributor based in Ukraine. The IDC has also issued a QCP MQAS certificate to Imres, an international pharmaceutical distributor based in the Netherlands. The certificate register ...
QUAMED Expands with Key Members: Empowering Pharmaceutical Quality Worldwide
QUAMED is happy to announce that its board of directors has accepted the Medical Export Group membership applications (in the Netherlands) and CHMP (in Kenya) as adherent members of our association. The board has also accepted the application of Mr. George Mugi as an associative member. We have been working and communicating with all three ...
Fatal Flaws: Unveiling the Human Toll of Compromised Drug Manufacturing
The recent Bloomberg post by Kendall Taggart and Priyanka Pulla highlights the tragic consequences of compromised drug manufacturing, specifically focusing on an Indian pharmaceutical supplier, Naprod Life Sciences. The narrative revolves around an investigative report shedding light on the distressing aftermath of contaminated medications distributed by Naprod. In Colombia, four children lost their lives, and over a hundred ...
Urgent Health Advisory: Substandard Medicines Alert – WHO N°8/2023
Medical Product Alert N°8/2023 Substandard (contaminated) syrup and suspension medicines have been identified in multiple WHO regions, including the Americas, Eastern Mediterranean, Southeast Asia, and the Western Pacific. Five products from PHARMIX LABORATORIES (PVT.) LTD, including ALERGO Syrup and ULCOFIN Suspension, have been found with dangerous levels of ethylene glycol, posing severe health risks like ...
Would you like more information about audits or get a quote? Do not hesitate to contact us via the contact form.